| 49.95 1.29 (2.65%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 61.2 | 1-year : | 71.48 |
| Resists | First : | 52.4 | Second : | 61.2 |
| Pivot price | 47.11 |
|||
| Supports | First : | 42.52 | Second : | 36.42 |
| MAs | MA(5) : | 49.42 |
MA(20) : | 44.91 |
| MA(100) : | 51.13 |
MA(250) : | 35.3 |
|
| MACD | MACD : | 1.9 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 76.6  |
D(3) : | 78.9 |
| RSI | RSI(14): 62 |
|||
| 52-week | High : | 72.29 | Low : | 14.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ APGE ] has closed below upper band by 29.6%. Bollinger Bands are 18.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 50.94 - 51.13 | 51.13 - 51.28 |
| Low: | 48.38 - 48.61 | 48.61 - 48.8 |
| Close: | 49.6 - 49.96 | 49.96 - 50.25 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Tue, 23 Jul 2024
Swiss National Bank Buys 8,300 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Tue, 23 Jul 2024
ProShare Advisors LLC Purchases Shares of 10,038 Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Tue, 23 Jul 2024
ProShare Advisors LLC Acquires New Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Sat, 20 Jul 2024
Reviewing Apogee Therapeutics (NASDAQ:APGE) and Anavex Life Sciences (NASDAQ:AVXL) - American Banking and Market News
Tue, 16 Jul 2024
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Up 18.0% in June - American Banking and Market News
Fri, 05 Jul 2024
Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 11.5 (%) |
| Held by Institutions | 106.5 (%) |
| Shares Short | 7,940 (K) |
| Shares Short P.Month | 6,500 (K) |
| EPS | -1.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.71 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.4 % |
| Return on Equity (ttm) | -22.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -96 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -27.15 |
| PEG Ratio | 0 |
| Price to Book value | 3.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|